Compare PK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | ADPT |
|---|---|---|
| Founded | 1946 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2019 |
| Metric | PK | ADPT |
|---|---|---|
| Price | $10.87 | $16.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $11.45 | ★ $16.60 |
| AVG Volume (30 Days) | ★ 3.4M | 2.7M |
| Earning Date | 10-30-2025 | 02-10-2026 |
| Dividend Yield | ★ 9.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,541,000,000.00 | $252,754,000.00 |
| Revenue This Year | N/A | $50.81 |
| Revenue Next Year | $2.07 | $1.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.57 |
| 52 Week Low | $8.27 | $5.91 |
| 52 Week High | $15.12 | $20.76 |
| Indicator | PK | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 50.47 |
| Support Level | $10.64 | $16.33 |
| Resistance Level | $10.94 | $17.04 |
| Average True Range (ATR) | 0.26 | 0.72 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 67.95 | 66.19 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).